Search Results

FDA Approves Boston Scientific's Innova Stent System for SFA/PPA Treatment

August 19, 2015—Boston Scientific Corporation announced that the company has received US Food and Drug Administration (FDA) approval for the Innova vascular self-expanding stent system to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA) or proximal popliteal artery (PPA).

Enrollment Completed in SuperNOVA Trial of Boston Scientific's Innova System for SFA/PPA Treatment

August 19, 2013—Boston Scientific Corporation (Natick, MA) announced that it has completed enrollment in the SuperNOVA trial.

Results Published From RESTORE-CLI Phase IIb Clinical Trial


April 5, 2012—Aastrom Biosciences, Inc. (Ann Arbor, MI), announced that final
results from the company's RESTORE-CLI phase IIb clinical trial for
ixmyelocel-T were published by Richard J. Powell, MD, et al in Molecular 
Therapy, the journal of the American Society of Gene & Cell Therapy. The phase IIb clinical results demonstrated that treatment with ixmyelocel-T improved time to treatment failure in patients with critical limb ischemia (CLI) compared to the control group. The subgroup of patients with wounds at baseline demonstrated an improvement in amputation-free survival. Ixmyelocel-T is an expanded, bone marrow-derived cellular therapy.



Boston Scientific Begins SuperNOVA Trial

April 5, 2011—Boston Scientific Corporation (Natick, MA) announced the start of patient enrollment in the SuperNOVA clinical trial.

Boston Scientific Begins Enrollment in SuperNOVA

April 5, 2011—Boston Scientific Corporation (Natick, MA) announced the start of patient enrollment in the SuperNOVA clinical trial.

IMPROVE Study Compares EVAR-First Strategy Versus Open Repair for Ruptured AAAs

April 16, 2015—One-year outcomes in the IMPROVE trial were published by Richard Grieve, MD, et al online ahead of print in the European Heart Journal.